ASCO GUIDELINES Bundle

Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475468

Contents of this Issue

Navigation

Page 5 of 71

6 Treatment Table A2: Immunosuppressive Agents Immunosuppressive Agents Dosing Indications Anakinra (Anti-IL1) 100 mg s.c. once a day Hematological irAEs Antithymocyte globulin (ATG) (Immune depletion) 500 mg on day 1, titrating the dose by 250 mg increments to daily CD2/3 levels (aiming for levels of 50–100/μl) for a total of 5 days. Hematological irAEs, severe cases of myocarditis Caplacizumab (Anti-vWF antibody) First day: 11 mg IV bolus at least 15 minutes before plasma exchange, followed by 11 mg SC aer completion of plasma exchange on day 1 Subsequent days during daily plasma exchange: 11 mg SC qd following plasma exchange Aer plasma exchange period: 11 mg SC qd for 30 days following last daily plasma exchange Aer initial treatment course: If sign(s) of persistent underlying disease, treatment may be extended for a maximum of 28 days Acquired thrombotic thrombocytopenic purpura Dupilumab (Anti-IL-4) Initial dose of 600 mg (two 300 mg injections in different injection sites), followed by 300 mg given every other week. Severe pruritic dermatitis Eculizumab (Anti-C5a) 900 mg weekly × 4 doses, 1,200 mg week 5, then 1,200 mg every two weeks HUS (cont'd)

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy